Braveheart Bio to Participate in Stifel Cardiometabolic Forum

Braveheart Bio will webcast its September 30 Stifel Cardiometabolic Forum fireside chat for investors and other interested viewers.

Rhea-AI Summary

Braveheart Bio (BRVE) will participate in the Stifel Virtual Cardiometabolic Forum on September 30, 2026. Management is scheduled for a fireside chat that day at 12:30 p.m. EDT.

Interested parties can access a live webcast of the session via the News & Events section of the Braveheart Bio investor relations website at https://ir.braveheart.bio/. A replay of the webcast will be available in a temporary archive on the site after the event.

Key Terms

hypertrophic cardiomyopathy

1 terms

hypertrophic cardiomyopathy medical

"developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM)"

Hypertrophic cardiomyopathy is a genetic heart condition in which the heart muscle becomes abnormally thick, making it harder for the heart to pump and for electrical signals to travel normally; think of a pump whose walls have thickened so it moves less efficiently. Investors care because the condition drives demand for diagnostics, drugs and devices, affects workforce and insurance costs, and can influence clinical trial results, regulatory approvals and liability exposure in healthcare-related companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Stifel Virtual Cardiometabolic Forum, being held September 30. Management will participate in a fireside chat on Wednesday, September 30, 2026, at 12:30 p.m. EDT.

Interested parties may access a live webcast by visiting the News & Events section of the Braveheart website at https://ir.braveheart.bio/, with a replay available in a temporary archive following the event.

About Braveheart Bio

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. For more information, please visit www.braveheart.bio.

Investor Relations Contact
Alexander Sharif
New Street Investor Relations
Alexander@NewStreetIR.com

Media Contact
FGS Global
Braveheart-bio@fgsglobal.com  

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can investors and other interested parties access Braveheart Bio's Stifel Forum presentation?

Access is available via a live webcast by visiting the News & Events section of Braveheart Bio's investor relations website at https://ir.braveheart.bio/.

Will a replay of the Braveheart Bio fireside chat be available after the Stifel Cardiometabolic Forum?

A replay of the webcast will be available in a temporary archive on Braveheart Bio's website following the event.

At what time and on what date is Braveheart Bio's fireside chat scheduled?

The fireside chat is scheduled for Wednesday, September 30, 2026, at 12:30 p.m. EDT.